[8-K] VIEMED HEALTHCARE, INC. Reports Material Event

(Moderate)

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Viemed Healthcare (VMD) furnished an 8-K to announce its financial results for the three and nine months ended September 30, 2025. The company provided a press release and a Financial Supplement as exhibits.

The materials are furnished under Item 2.02 and, under General Instruction B.2, are not deemed filed or subject to Section 18 liabilities. Exhibits include the press release (99.1) and Financial Supplement (99.2), both dated November 5, 2025.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/05/2025 - 04:38 PM

FAQ

What did Viemed Healthcare (VMD) announce in this 8-K?

Viemed furnished its financial results for the three and nine months ended September 30, 2025, via a press release and a Financial Supplement.

Which exhibits were included with VMD’s 8-K?

Exhibit 99.1 is the press release dated November 5, 2025, and Exhibit 99.2 is the Financial Supplement dated November 5, 2025.

Are the Q3 2025 materials considered filed with the SEC?

No. Under General Instruction B.2, the information, including Exhibits 99.1 and 99.2, is furnished and not deemed filed under Section 18.

What period do the results cover for VMD?

The results cover the three and nine months ended September 30, 2025.

What is Viemed Healthcare’s trading symbol and exchange?

The common shares trade on The Nasdaq Stock Market LLC under the symbol VMD.

When were the exhibits dated?

Both the press release and the Financial Supplement are dated November 5, 2025.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2025

Viemed Healthcare, Inc.

(Exact name of registrant as specified in its charter)

British Columbia, Canada

001-38973

N/A

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)



625 E. Kaliste Saloom Rd. Lafayette, Louisiana						70508
(Address of principal executive offices)						(Zip Code)

(337) 504-3802

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common shares, no par value	VMD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 5, 2025, Viemed Healthcare, Inc. (the "Company") issued a press release announcing its financial results for the three and nine months ended September 30, 2025. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In addition, the Company issued a Financial Supplement with respect to its financial results for the three and nine months ended September 30, 2025. The Financial Supplement is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the foregoing information, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information and Exhibits 99.1 and 99.2 be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits


			(d)			Exhibits


Exhibit Number						Description

99.1 Press Release dated November 5, 2025.

99.2 Financial Supplement dated November 5, 2025.

104 Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 5, 2025



VIEMED HEALTHCARE, INC.

By:						/s/ Trae Fitzgerald
						Trae Fitzgerald
						Chief Financial Officer

Source: View Original Filing on SEC EDGAR